NMRA

Neumora Therapeutics, Inc. (NMRA) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases using a precision neuroscience approach. The company has no approved products and has not generated any revenue from product sales. Its most advanced asset is navacaprant (NMRA-140), a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder (MDD).

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by $38.3 million (52%) compared to the same period in 2023, driven primarily by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses rose $32.1 million year-over-year for the six-month period. This increase was primarily due to a $41.0 million increase in direct external program expenses for the navacaprant Phase 3 clinical trials, partially offset by a decrease in contracted research activities with Amgen.
• Stock-Based Compensation: Total stock-based compensation increased significantly to $20.1 million for the six months ended June 30, 2024, compared to $4.7 million in the prior year period. This includes $3.7 million in modification expenses related to restricted stock awards.
• Liquidity Position: While cash and cash equivalents decreased from $374.0 million at year-end 2023 to $150.7 million at June 30, 2024, the company increased its holdings in short-term marketable securities to $221.0 million. Total liquid assets remain at $371.6 million.

Guidance, Outlook, and Risks

• Clinical Milestones: The company anticipates releasing topline results from the KOASTAL-1 Phase 3 study for navacaprant in the fourth quarter of 2024. Results for KOASTAL-2 and KOASTAL-3 are expected in the first half of 2025. A Phase 2 study for navacaprant in bipolar depression was initiated in May 2024, with results expected in the second half of 2025.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities are sufficient to fund operations for at least the next 12 months from the date of the report. The company expects to incur additional losses as it advances clinical programs and will require substantial additional funding for future operations and commercialization.
• Key Risks:
  • Clinical Holds: The Phase 1 trial for NMRA-266 was placed on clinical hold by the FDA in April 2024 following nonclinical data showing convulsions in rabbits. The company is working with the FDA to resolve this.
  • Contingent Consideration: The company has significant potential future obligations from acquisitions (BlackThorn, Vanderbilt, Amgen) totaling hundreds of millions of dollars in milestones, which could be settled in cash or stock, potentially causing dilution.
  • Regulatory and Development Risk: As a clinical-stage company with no approved products, success depends on the outcome of clinical trials and regulatory approvals, which are inherently uncertain.

Investor Verification Checklist

• Verify the status and timeline for the resolution of the FDA clinical hold on the NMRA-266 Phase 1 trial.
• Monitor the upcoming Q4 2024 topline data release for the KOASTAL-1 Phase 3 study of navacaprant.
• Review the company's cash burn rate and confirm the 12-month liquidity runway given the increased R&D spend.
• Assess the potential dilution impact of future milestone payments, particularly those payable in stock under the BlackThorn and Vanderbilt agreements.
• Confirm the progress of the Phase 2 bipolar depression study initiated in May 2024.